BRNS Stock: Barinthus Biotherapeutics plc Stock Price, Analysis & Insights
Get live BRNS stock price $0.72, comprehensive Barinthus Biotherapeutics plc stock analysis, charts, news, and expert forecast. Real-time BRNS stock data and investment insights.
Loading chart data...
Investment Score
A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's own immune system to effectively combat chronic i...
Company Information
- CEO
- William James Enright
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 105
Contact Information
- Website
- https://www.barinthusbio.com
- Address
- Zeus Building
- Country
- GB
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Lower volatility stock (Beta: -0.40) may provide portfolio stability
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Barinthus Biotherapeutics plc shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Barinthus Biotherapeutics plc
- ⚠Investors should consider how Barinthus Biotherapeutics plc fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
29.57M
P/E Ratio (TTM)
-0.56
Beta
-0.40
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare BRNS with peer companies:
- Price
- $5.14
- Market cap
- 31.81M
- Price
- $1.30
- Market cap
- 8.93M
- Price
- $1.22
- Market cap
- 32.43M
- Price
- $8.69
- Market cap
- 196.94M
- Price
- $7.29
- Market cap
- 53.86M
- Price
- $0.32
- Market cap
- 7.11M
- Price
- $29.08
- Market cap
- 145.36M
- Price
- $4.25
- Market cap
- 58.11M
- Price
- $0.91
- Market cap
- 23.81M
- Price
- $1.27
- Market cap
- 5.64M
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.